57.
Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003;169(5):1706–8.PubMed
58.
Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol. 2000;164(3 Pt 1):685–9.PubMed
59.
Gallagher BL, Joudi FN, Maymí JL, O’Donnell MA. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology. 2008;71(2):297–301.PubMed
60.
Joudi FN, Smith BJ, O’Donnell MA, National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24(4):344–8.PubMed
61.
Olsson CA, Chute R, Rao CN. Immunologic reduction of bladder cancer recurrence rate. J Urol. 1974;111(2):173–6.PubMed
62.
Lamm DL, DeHaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol. 2000;37 Suppl 3:41–4.PubMed
63.
Kowalski M, Entwistle J, Cizeau J, et al. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients. Drug Des Devel Ther. 2010;4:313–20.PubMedCentralPubMed
< div class='tao-gold-member'>
Only gold members can continue reading. Log In or Register a > to continue